Clinical medicine profile
Terbutaline Sulphate 1.25mg+Ammonium Chloride 60mg+Sodium Citrate 25mg/5mL
Beta-2 adrenergic agonist (bronchodilator)
- Route
- INHALATION / ORAL / NEB / IV (rare)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Terbutaline Sulphate] Hypersensitivity.
- LABA monotherapy in asthma is contraindicated — always with ICS. [Ammonium Chloride] [Ammonium chloride] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Paradoxical bronchospasm.
- Hypokalaemia with high dose/nebs especially with steroids/diuretics/xanthines.
- CV disease: tachycardia/arrhythmia risk.
- Thyrotoxicosis caution.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Children 3 - 6 yrs: 2.5 mL- 5 mL TID. 7 yrs and older:5 mL-10 mL TID.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Low for inhaled; monitor electrolytes if continuous nebs.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Low clinical concern for inhaled therapy.
Use, effects & interactions
Indications
- Cough associated with bronchospasm in children.
- Clinical selection for Terbutaline Sulphate 1.25mg+Ammonium Chloride 60mg+Sodium Citrate 25mg/5mL should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Beta-2 adrenergic agonist (bronchodilator).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- [From component Terbutaline sulphate] Tachycardia, skeletal muscle cramp, palpitation, headaches, severe emotional disturbances, resistance after prolonged use, acidosis, GI disturbances, hypokaleamia, sweat
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Terbutaline sulphate.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Terbutaline sulphate): It stimulates Beta-agonist in the lungs to relax bronchial smooth muscle, thereby relieving bronchospasm. This action may result from increased production of cAMP and ensuing reduction in intracellular calcium concentration caused by activation of the enzyme adenylate cyclase that catalyzes the conversion ATP to cAMP. Increased cAMP concentrations, in addition to relaxing bronchial smooth muscle, inhibit release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Minutes (SABA)
3–6 h SABA; 12 h LABA
INHALATION / ORAL / NEB / IV (rare)
causes tremor/tachycardia. Hepatic
of many agents. [Ammonium Chloride]
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
[Terbutaline Sulphate] Inhaled salbutamol widely used; uncontrolled asthma risk > drug risk. [Ammonium Chloride] [Ammonium chloride] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Inhaled therapy generally compatible.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.